Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

Press ReleaseNicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025New Drug Application (NDA) submission in the U.S. targeted for H1 2026June 30, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the...

Biot, 30/06/2025 (informazione.news - comunicati stampa - salute e benessere)

Attachment